What type of lung cancer is Vizimpro used to treat?
Medically reviewed by Drugs.com. Last updated on Oct 28, 2020.
Official Answer
by Drugs.comVizimpro is taken for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Vizimpro (dacomitinib) from Pfizer is an oral, once-daily kinase inhibitor that targets two lung cancer biomarkers, both detected by an FDA-approved test. These two targets are:- Epidermal growth factor receptor (EGFR) exon 19 deletion mutations
- EGFR exon 21 L858R substitution mutations.
Other EGFR inhibitors that may be used in the treatment of NSCLC include:
Related Medical Questions
- Oxycodone vs Hydrocodone - How do they compare?
- Vicodin vs Percocet: What's the difference?
- Is Sprycel a chemotherapy drug?
- How does Ibrance kill cancer?
- Can Darzalex cure Multiple Myeloma?
- What are the side effects of marijuana?
- My stool has changed color. What does it mean?
- Does Cabometyx (cabozantinib) cure cancer?
- Is Darzalex chemotherapy?
- Is lenvatinib / pembrolizumab used in endometrial cancer?
- How are axitinib and pembrolizumab used in kidney cancer?
- How effective is Herceptin for Breast & Gastric Cancer?
- How effective is Alecensa for ALK-positive NSCLC?
- What type of prostate cancer is Erleada used to treat?
- What type of cancer is Tecentriq used to treat?
Drug Information
Related Support Groups
- Vizimpro (1 questions, 3 members)
- Dacomitinib (1 questions, 3 members)
- Cancer (101 questions, 601 members)
- Non-Small Cell Lung Cancer (18 questions, 60 members)
- Lung Cancer (5 questions, 36 members)